Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Shares Issued (2016 - 2024)

Ultragenyx Pharmaceutical (RARE) has disclosed Shares Issued for 8 consecutive years, with $381.0 million as the latest value for Q2 2024.

  • Quarterly Shares Issued changed N/A to $381.0 million in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $390.1 million through Jun 2024, changed N/A year-over-year, with the annual reading at $6.0 million for FY2025, 45.45% down from the prior year.
  • Shares Issued for Q2 2024 was $381.0 million at Ultragenyx Pharmaceutical, up from $2.0 million in the prior quarter.
  • The five-year high for Shares Issued was $381.0 million in Q2 2024, with the low at $380000.0 in Q1 2020.
  • Average Shares Issued over 4 years is $45.3 million, with a median of $9.8 million recorded in 2021.
  • Peak annual rise in Shares Issued hit 6500.5% in 2020, while the deepest fall reached 99.88% in 2020.
  • Over 4 years, Shares Issued stood at $79.8 million in 2020, then plummeted by 91.32% to $6.9 million in 2021, then tumbled by 71.1% to $2.0 million in 2022, then soared by 18940.48% to $381.0 million in 2024.
  • According to Business Quant data, Shares Issued over the past three periods came in at $381.0 million, $2.0 million, and $1.1 million for Q2 2024, Q4 2022, and Q3 2022 respectively.